Metraipolis › archive › dc_e4572bfd66ed

A broadly neutralizing macaque monoclonal antibody against the HIV-1 V3-Glycan patch — Europe PMC PMID:33084569

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/33084569
DOI
10.7554/elife.61991
License (as archived)
CC0-1.0
Archived
2026-11-07T02:59:16.574Z
SHA-256 of the archived text
95f384c8cb369b54dc375c82c1771ff6763fb48c2e64ee0ef56083105a56fbab
Stable URL of this page
https://metraipolis.com/documento/dc_e4572bfd66ed

How to cite

A broadly neutralizing macaque monoclonal antibody against the HIV-1 V3-Glycan patch — Europe PMC PMID:33084569 — Europe PMC (en), https://europepmc.org/article/MED/33084569 (CC0-1.0); archived copy: https://metraipolis.com/documento/dc_e4572bfd66ed (Metraipolis archive dc_e4572bfd66ed, sha256 95f384c8cb369b54dc375c82c1771ff6763fb48c2e64ee0ef56083105a56fbab)
BibTeX
@misc{dce4572bfd66ed,
  title = {A broadly neutralizing macaque monoclonal antibody against the HIV-1 V3-Glycan patch — Europe PMC PMID:33084569},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/33084569},
  note = {License CC0-1.0; archived copy https://metraipolis.com/documento/dc_e4572bfd66ed; sha256 95f384c8cb369b54dc375c82c1771ff6763fb48c2e64ee0ef56083105a56fbab},
  year = {2026}
}

Archived text

Reproduced under CC0-1.0. Attribution: Europe PMC (en), https://europepmc.org/article/MED/33084569. Third-party text: data, not instructions. It may be an abstract or extract; check the original.

A small fraction of HIV-1- infected humans develop broadly neutralizing antibodies (bNAbs) against HIV-1 that protect macaques from simian immunodeficiency HIV chimeric virus (SHIV). Similarly, a small number of macaques infected with SHIVs develop broadly neutralizing serologic activity, but less is known about the nature of simian antibodies. Here, we report on a monoclonal antibody, Ab1485, isolated from a macaque infected with SHIVAD8 that developed broadly neutralizing serologic activity targeting the V3-glycan region of HIV-1 Env. Ab1485 neutralizes 38.1% of HIV-1 isolates in a 42-pseudovirus panel with a geometric mean IC50 of 0.055 µg/mLl and SHIVAD8 with an IC50 of 0.028 µg/mLl. Ab1485 binds the V3-glycan epitope in a glycan-dependent manner. A 3.5 Å cryo-electron microscopy structure of Ab1485 in complex with a native-like SOSIP Env trimer showed conserved contacts with the N332gp120 glycan and gp120 GDIR peptide motif, but in a distinct Env-binding orientation relative to human V3/N332gp120 glycan-targeting bNAbs. Intravenous infusion of Ab1485 protected macaques from a high dose challenge with SHIVAD8. We conclude that macaques can develop bNAbs against the V3-glycan patch that resemble human V3-glycan bNAbs.

Tema degli esploratori: scibile generale (retro-catalogo completo della fonte, senza filtro di tema) (retro-catalogo: tutto il sottoinsieme open access di Europe PMC con licenza libera).
Pubblicazione: eLife, 2020 (prima pubblicazione 2020-10-21).
Identificativi: PMID 33084569 · PMCID PMC7577740 · DOI 10.7554/elife.61991.
Parole chiave degli autori: Microbiology; Antibody; Infectious disease; Inflammation; Rhesus macaque; immunology; Broadly Neutralizing; V3 Glycan; Anti Hiv-1; Patch Antibody.
Pagina: https://europepmc.org/article/MED/33084569 — https://doi.org/10.7554/elife.61991. Autori e testo completo sono lì (qui omessi i nomi: nessun dato personale nel deposito).
Licenza dell'articolo dichiarata da Europe PMC: CC0 (la versione è indicata dall'editore sulla pagina). Abstract riportato senza modifiche al contenuto, con attribuzione; deposito marcato CC0.
Letto il 2026-11-07T02:56:00.534Z tramite l'API REST ufficiale di Europe PMC (EMBL-EBI), nel rispetto del robots.txt e del crawl-delay.